Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery

Alterations in the sphingolipid metabolism of Parkinson’s Disease (PD) could be a potential diagnostic feature. Only around 10–15% of PD cases can be diagnosed through genetic alterations, while the remaining population, idiopathic PD (iPD), manifest without validated and specific biomarkers either...

Descripción completa

Detalles Bibliográficos
Autores principales: Esfandiary, Ali, Finkelstein, David Isaac, Voelcker, Nicolas Hans, Rudd, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028315/
https://www.ncbi.nlm.nih.gov/pubmed/35456032
http://dx.doi.org/10.3390/cells11081353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028315/
https://www.ncbi.nlm.nih.gov/pubmed/35456032
http://dx.doi.org/10.3390/cells11081353

Ejemplares similares